BRIEF-PTC Therapeutics Provides Regulatory Update On Translarna™ (Ataluren) In Europe

Reuters2025-03-28

BRIEF-PTC <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Provides Regulatory Update On Translarna™ (Ataluren) In Europe

March 28 (Reuters) - PTC Therapeutics Inc PTCT.O:

PTC THERAPEUTICS PROVIDES REGULATORY UPDATE ON TRANSLARNA™ (ATALUREN) IN EUROPE
PTC THERAPEUTICS : DISAPPOINTED THAT AFTER PROLONGED PERIOD OF REVIEW EUROPEAN COMMISSION HAS DECIDED TO ADOPT CHMP NEGATIVE OPINION ON TRANSLARNA
PTC THERAPEUTICS INC: LOOK FORWARD TO WORKING ON A COUNTRY-BY-COUNTRY BASIS TO PROVIDE COMMERCIAL DRUG WHERE POSSIBLE
PTC THERAPEUTICS INC: THIS ACTION EFFECTIVELY REMOVES DRUG'S CONDITIONAL MARKETING AUTHORIZATION IN EUROPEAN ECONOMIC AREA
PTC THERAPEUTICS : EC HAS ADOPTED OPINION OF COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE OF EMA TO NOT RENEW AUTHORIZATION OF TRANSLARNA

Source text: ID:nPn9ZXWY8a

Further company coverage: PTCT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522572325?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-28 21:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522572325","market":"us","top_or_hot":-1,"title":"BRIEF-PTC Therapeutics Provides Regulatory Update On Translarna™ (Ataluren) In Europe","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Provides Regulatory Update On Translarna™ (Ataluren) In Europe</title></head><body><p><span>March 28 (Reuters)</span><span> - </span>PTC Therapeutics Inc <span>PTCT.O</span>:</p><ul><li><p>PTC THERAPEUTICS PROVIDES REGULATORY UPDATE ON TRANSLARNA™ (ATALUREN) IN EUROPE</p></li><li><p>PTC THERAPEUTICS : DISAPPOINTED THAT AFTER PROLONGED PERIOD OF REVIEW EUROPEAN COMMISSION HAS DECIDED TO ADOPT CHMP NEGATIVE OPINION ON TRANSLARNA</p></li><li><p>PTC THERAPEUTICS INC: LOOK FORWARD TO WORKING ON A COUNTRY-BY-COUNTRY BASIS TO PROVIDE COMMERCIAL DRUG WHERE POSSIBLE</p></li><li><p>PTC THERAPEUTICS INC: THIS ACTION EFFECTIVELY REMOVES DRUG'S CONDITIONAL MARKETING AUTHORIZATION IN EUROPEAN ECONOMIC AREA</p></li><li><p>PTC THERAPEUTICS : EC HAS ADOPTED OPINION OF COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE OF EMA TO NOT RENEW AUTHORIZATION OF TRANSLARNA</p></li></ul><p>Source text: <span>ID:nPn9ZXWY8a</span></p><p>Further company coverage: <span>PTCT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-PTC Therapeutics Provides Regulatory Update On Translarna™ (Ataluren) In Europe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-PTC Therapeutics Provides Regulatory Update On Translarna™ (Ataluren) In Europe\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-28 21:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Provides Regulatory Update On Translarna™ (Ataluren) In Europe</title></head><body><p><span>March 28 (Reuters)</span><span> - </span>PTC Therapeutics Inc <span>PTCT.O</span>:</p><ul><li><p>PTC THERAPEUTICS PROVIDES REGULATORY UPDATE ON TRANSLARNA™ (ATALUREN) IN EUROPE</p></li><li><p>PTC THERAPEUTICS : DISAPPOINTED THAT AFTER PROLONGED PERIOD OF REVIEW EUROPEAN COMMISSION HAS DECIDED TO ADOPT CHMP NEGATIVE OPINION ON TRANSLARNA</p></li><li><p>PTC THERAPEUTICS INC: LOOK FORWARD TO WORKING ON A COUNTRY-BY-COUNTRY BASIS TO PROVIDE COMMERCIAL DRUG WHERE POSSIBLE</p></li><li><p>PTC THERAPEUTICS INC: THIS ACTION EFFECTIVELY REMOVES DRUG'S CONDITIONAL MARKETING AUTHORIZATION IN EUROPEAN ECONOMIC AREA</p></li><li><p>PTC THERAPEUTICS : EC HAS ADOPTED OPINION OF COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE OF EMA TO NOT RENEW AUTHORIZATION OF TRANSLARNA</p></li></ul><p>Source text: <span>ID:nPn9ZXWY8a</span></p><p>Further company coverage: <span>PTCT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0889565916.HKD","symbol_name":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0YI:1","article_id":"2522572325","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522572325","pubTimestamp":1743167794,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-PTC Therapeutics Provides Regulatory Update On Translarna (Ataluren) In EuropeMarch 28 (Reuters) - PTC Therapeutics Inc PTCT.O:PTC THERAPEUTICS PROVIDES REGULATORY UPDATE ON TRANSLARNA (ATALUREN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","PTCT":"PTC Therapeutics Inc.","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"简介-PTC Therapeutics提供Translarna™(Ataluren)在欧洲的监管更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTCT":0.9},"content_text":"BRIEF-PTC Therapeutics Provides Regulatory Update On Translarna™ (Ataluren) In EuropeMarch 28 (Reuters) - PTC Therapeutics Inc PTCT.O:PTC THERAPEUTICS PROVIDES REGULATORY UPDATE ON TRANSLARNA™ (ATALUREN) IN EUROPEPTC THERAPEUTICS : DISAPPOINTED THAT AFTER PROLONGED PERIOD OF REVIEW EUROPEAN COMMISSION HAS DECIDED TO ADOPT CHMP NEGATIVE OPINION ON TRANSLARNAPTC THERAPEUTICS INC: LOOK FORWARD TO WORKING ON A COUNTRY-BY-COUNTRY BASIS TO PROVIDE COMMERCIAL DRUG WHERE POSSIBLEPTC THERAPEUTICS INC: THIS ACTION EFFECTIVELY REMOVES DRUG'S CONDITIONAL MARKETING AUTHORIZATION IN EUROPEAN ECONOMIC AREAPTC THERAPEUTICS : EC HAS ADOPTED OPINION OF COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE OF EMA TO NOT RENEW AUTHORIZATION OF TRANSLARNASource text: ID:nPn9ZXWY8aFurther company coverage: PTCT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522572325","isCrawlerRequest":true}